Previous Article | Next Article ![]()
Journal of Clinical Microbiology, June 2001, p. 2157-2165, Vol. 39, No. 6
ARUP Institute for Clinical and Experimental
Pathology,1 and Department of
Pathology, University of Utah Health Sciences
Center,2 Salt Lake City, Utah
Received 29 November 2000/Returned for modification 30 January
2001/Accepted 14 March 2001
The use of genotypic assays for determining drug resistance in
human immunodeficiency virus (HIV) type 1 (HIV-1)-infected patients is increasing. These tests lack standardization and
validation. The aim of this study was to evaluate several tests used
for the determination of HIV-1 drug resistance. Two genotypic tests,
the Visible Genetics TruGene HIV-1 Genotyping Kit and the Applied Biosystems HIV Genotyping System, were compared using 22 clinical samples. Genotyping results were also obtained from an independent reference laboratory. The Visible Genetics and Applied Biosystems genotyping tests identified similar mutations when differences in the
drug databases and reference strains were taken into account, and 19 of
21 samples were equivalent. The concordance between the two assays was
99% (249 of 252 mutation sites). Mutations identified by the reference
laboratory varied the most among those identified by the three
genotypic tests, possibly because of differences in the databases. The
concordance of the reference laboratory results with the results of the
other two assays was 80% (201 of 252). Samples with 500 to 750 HIV RNA
copies/ml could be sequenced by the Visible Genetics and Applied
Biosystems assays using 1 ml of input. The Visible Genetics and Applied
Biosystems assays both generated an accurate sequence. However, the
throughput of the Visible Genetics assay is more limited and may
require additional instruments. The two assays differ technically but
are similar in overall complexity. Data analysis in the two assays is
straightforward, but only the reports provided by Visible Genetics
contain information relating mutations to drug resistance. HIV drug
resistance genotyping by sequencing is a complex technology which
presents a challenge for analysis, interpretation, and reporting.
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.6.2157-2165.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Human Immunodeficiency Virus Type 1 Drug Resistance Testing:
a Comparison of Three Sequence-Based Methods
*
Corresponding author. Mailing address: ARUP Institute
for Clinical and Experimental Pathology, 500 Chipeta Way, Salt Lake City, UT 84108. Phone: (801) 583-2787, ext. 2312. Fax: (801) 584-5207. E-mail: eralimc{at}arup-lab.com.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»